<DOC>
	<DOCNO>NCT02548806</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic dose proportionality 50 μg 100 μg Clonidine comparative bioavailability clonidine Reference drug , Catapres® 100 μg oral tablet follow single dose administration healthy subject .</brief_summary>
	<brief_title>Phase 1 PK , Bioavailability , Safety Study Clonidine MBT w Catapres Healthy Volunteers</brief_title>
	<detailed_description>A single blind , randomise , 3-period , 3-sequence single-dose crossover study determine pharmacokinetic dose proportionality Clonidine MBT 50 μg Clonidine MBT 100 μg comparative bioavailability clonidine Reference drug , Catapres® 100 μg oral tablet follow single dose administration healthy male female subject . 36 subject randomise 30 complete study . The study comprise 3 Treatment Periods ( 1 , 2 3 ) post study follow ( 7 - 12 day last dose ) . Study drug administer morning Day 1 . Pharmacokinetic ( PK ) blood sample collect three treatment period . Safety evaluate specify time throughout study . There least 7 day dose administration .</detailed_description>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Main Healthy male female ( nonpregnant/nonlactating ) age 18 50 year . A Body Mass Index ( BMI ) 1830 . No clinically significant abnormal serum biochemistry , haematology urine examination value . A negative urinary drug abuse screen . Negative HIV Hepatitis B C result . No clinically significant abnormality 12lead electrocardiogram ( ECG ) . No clinically significant abnormality blood pressure pulse . No allergy sensitivity clonidine excipients . No allergy milk milk derivative . Subjects must provide write informed consent participate study Main Current past medical condition might significantly affect pharmacokinetic pharmacodynamic response clonidine . Participation New Chemical Entity clinical study within previous 3 month market drug clinical study within previous 30 day . Pathological condition oral cavity would affect administration via buccal route . Raynaud 's disease peripheral vascular disease . Receipt regular medication within 14 day first dose may impact safety objective study ( Investigator 's discretion ) . Evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . Symptomatic postural hypotension evident screen History evidence Suicidal Ideation and/or behaviour determine use ColumbiaSuicide Severity Rating Scale ( CSSRS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Clonidine</keyword>
</DOC>